Jonathan Steinberg, HRS 2019 – the ERADICATE-AF study
Professor Jonathan Steinberg (Professor of Medicine, University of Rochester School of Medicine, Rochester, NY, USA) spoke with us at Heart Rhythm 2019 about the main challenges of treating patients with resistant hypertension and atrial fibrillation, and the rationale and results of the ERADICATE-AF study.
Filmed at Heart Rhythm 2019, San Francisco, CA, USA.
Speaker’s Disclosures: Jonathan Steinberg has nothing to declare in relation to this interview.
1. What are the main challenges you face when treating patients with resistant hypertension and atrial fibrillation? (0:10)
2. What was the rationale behind the Evaluate Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation (ERADICATE-AF) study? (0:49)
3. What were the key findings of the ERADICATE-AF study? (2:00)
4. What are the next steps in this area of research? (3:18)
5. What are your highlights from Heart Rhythm 2019? (4:09)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed in partnership with Arrhythmia Alliance.
Share this Video
Related Videos In Hypertension
Kelly Chin, ACC 2023: The treatment paradigm for patients with pulmonary arterial hypertension
Recommended therapy for patients with pulmonary arterial hypertension is generally a combination of an endothelin receptor antagonist and a phosphodiesterase type 5 inhibitor. In this touchCARDIO interview, we speak with Dr Kelly Chin (UT Southwestern Medical Centre, Dallas, TX, USA) to discuss the treatment paradigm. Dr Chin presented an abstract entitled ‘Efficacy And Safety Of […]
Kelly Chin, ACC 2023: A DUE phase III study, a macitentan and tadalafil combination for patients with pulmonary arterial hypertension
The aim of the A DUE study was to assess the combination of macitentan and tadalafil for patients with pulmonary arterial hypertension. In this touchCARDIO interview, we speak with Dr Kelly Chin (UT Southwestern Medical Centre, Dallas, TX, USA) to discuss the findings of the trial and the clinical impact. The abstract entitled ‘Efficacy And […]
Marius Hoeper, ACC 2023: STELLAR phase III trial results – Sotatercept for the treatment of pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a progressive disease involving proliferative remodeling of the pulmonary vessels and elevations in pulmonary vascular resistance (PVR). Despite recent treatment advances, the associated morbidity and mortality rates of the disease are still high. In this touchCARDIO interview, we speak with Prof. Marius Hoeper (Department of Respiratory Medicine, Hannover Medical School, Hannover, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!